Antisense RNA medicines can treat diseases like Huntington’s disease that are caused by excess or defective proteins.
Antisense RNA works by binding to messenger RNA (mRNA) and physically preventing the cell from translating the mRNA into protein. When antisense RNA binds to mRNA, it also signals the cell to destroy the mRNA. These mechanisms are called RNA interference, or RNAi, because they stop the protein product of a particular gene from being produced. Each antisense RNA targets and inhibits one specific mRNA.
Antisense RNAs are quickly degraded inside cells, so antisense RNA medicines can have low potency and efficiency. These problems can be overcome by using Arcturus’ unlocked nucleomonomer agent (UNA) Oligomer technology. The enzymes that destroy RNA inside cells cannot recognize UNAs. Therefore, antisense RNAs that contain UNAs are protected from degradation.
July 23, 2018
Arcturus Therapeutics Achieves Program Milestones and Refines Agreement with Cystic Fibrosis Foundation Therapeutics
July 20, 2018
Arcturus Therapeutics Announces Annual and Extraordinary General Meeting of Shareholders to Be Held on August 24, 2018
July 9, 2018
Arcturus Therapeutics Announces Results of Extraordinary General Meeting of Shareholders